Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PLIANT THERAPEUTICS, INC. (PLRX)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 0.2 | 1.3 | 2.0 | 1.5 | 5.0 | 1.2 | 2.0 | 1.6 |
| Revenue growth | -95.0% | 6.6% | -1.7% | -8.0% | 178.9% | -42.5% | -55.2% | -66.6% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.2 | 1.3 | 2.0 | 1.5 | 5.0 | 1.2 | 2.0 | 1.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative [+] | 14.6 | 14.2 | 14.3 | 8.8 | 8.3 | 8.6 | 7.8 | 7.7 |
| General and administrative | 14.6 | 14.2 | 14.3 | 8.8 | 8.3 | 8.6 | 7.8 | 7.7 |
| Research and development | 33.0 | 29.3 | 25.1 | 24.6 | 26.3 | 20.9 | 18.8 | 21.1 |
| EBITDA [+] | -46.9 | -41.6 | -36.9 | -31.5 | -29.2 | -27.8 | -24.2 | -26.7 |
| EBITDA growth | 60.5% | 50.0% | 52.8% | 17.8% | 29.5% | 23.0% | 29.5% | 63.6% |
| EBITDA margin | -18891.5% | -3126.4% | -1880.2% | -2125.0% | -584.9% | -2222.3% | -1209.7% | -1659.9% |
| Depreciation and amortization | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 |
| EBIT [+] | -47.3 | -42.1 | -37.4 | -31.9 | -29.6 | -28.2 | -24.6 | -27.1 |
| EBIT growth | 59.7% | 49.2% | 52.0% | 17.8% | 29.4% | 23.1% | 29.4% | 62.7% |
| EBIT margin | -19083.9% | -3160.3% | -1903.3% | -2155.7% | -594.1% | -2258.7% | -1230.6% | -1684.0% |
| Interest expense | 0.3 | 0.3 | | | 0.2 | | | |
| Interest expense | 0.3 | 0.3 | | | 0.2 | | | |
| Other income (expense), net | 6.5 | 4.9 | 2.3 | 1.3 | 0.3 | 0.1 | 0.1 | 0.1 |
| Pre-tax income | -41.2 | -37.5 | -35.1 | -30.6 | -29.5 | -28.1 | -24.5 | -27.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -41.2 | -37.5 | -35.1 | -30.6 | -29.5 | -28.1 | -24.5 | -27.0 |
| Net margin | -16609.7% | -2818.9% | -1784.2% | -2065.8% | -592.2% | -2249.8% | -1227.2% | -1679.8% |
| |
| Basic EPS [+] | ($0.70) | ($0.67) | ($0.83) | ($0.65) | ($0.82) | ($0.78) | ($0.68) | ($0.75) |
| Growth | -14.8% | -13.9% | 21.9% | -13.1% | 27.9% | 21.3% | -23.2% | 61.5% |
| Diluted EPS [+] | ($0.70) | ($0.67) | ($0.83) | ($0.65) | ($0.82) | ($0.78) | ($0.68) | ($0.75) |
| Growth | -14.8% | -13.9% | 21.9% | -13.1% | 27.9% | 21.3% | -23.2% | 61.5% |
| |
| |
| Shares outstanding (basic) [+] | 59.2 | 56.1 | 42.0 | 46.8 | 36.2 | 36.1 | 35.8 | 35.9 |
| Growth | 63.6% | 55.2% | 17.2% | 30.3% | 1.2% | 1.3% | 67.9% | 1.3% |
| Shares outstanding (diluted) [+] | 59.2 | 56.1 | 42.0 | 46.8 | 36.2 | 36.1 | 35.8 | 35.9 |
| Growth | 63.6% | 55.2% | 17.2% | 30.3% | 1.2% | 1.3% | 67.9% | 1.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|